Market Data
Market Cap₹180.91 Cr.
52W High₹56.99
Current Price₹21.8
52W Low₹20.6
Down from 52W High61.7 %
Face Value₹2
Performance
ROCE22.07 %
ROE18.31 %
EPS (TTM)₹0.3
EPS Prev Qtr₹0.71
EPS Last Year₹0.31
EBITDA Qtr₹2.58 Cr.
Book Value₹9
Financial Health
Debt/Equity0.25
Debt/Profit1.39
Total Assets₹153.4 Cr.
Promoter Holding61.38 %
Earning Power9.42 %
Valuation
Stock P/E13.05
Industry P/E33.3
Price to Book2.4
Price to Sales0.76
Graham Number₹18.47
Key Metrics
__derived
1
Face Value
₹2
About Medico Remedies Ltd
Healthcare · Pharmaceuticals
Medico Remedies Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹180.91 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 81.4% YoY, Profit grew 38.5% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 38.25 | 52.64 | 58.68 | 56.81 | 69.4 |
| ↳ QoQ Growth | - | +37.6% | +11.5% | -3.2% | +22.2% |
| Expenses | 36.2 | 50.65 | 55.14 | 50.46 | 66.82 |
| Operating Profit | 2.06 | 1.98 | 3.54 | 6.35 | 2.58 |
| OPM % | 5.39% | 3.76% | 6.03% | 11.18% | 3.72% |
| Other Income | 0.66 | 1.72 | 0.68 | 2.87 | 1.17 |
| Interest | 0.28 | 0.24 | 0.39 | 0.9 | 0.41 |
| Depreciation | 0.77 | 0.73 | 0.79 | 0.8 | 0.72 |
| EBITDA | 2.83 | 2.71 | 4.33 | 7.15 | 3.3 |
| EBITDA Margin % | 7.4% | 5.15% | 7.38% | 12.59% | 4.76% |
| Profit Before Tax | 2.44 | 3.47 | 3.83 | 8.32 | 3.34 |
| Tax % | 25% | 26.22% | 25.07% | 29.57% | 24.55% |
| Net Profit | 1.82 | 2.57 | 2.87 | 5.86 | 2.52 |
| ↳ QoQ Growth | - | +41.2% | +11.7% | +104.2% | -57.0% |
| EPS | 0.22 | 0.31 | 0.35 | 0.71 | 0.3 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 206.38 | 237.53 |
| Expenses | 192.45 | 223.07 |
| Operating Profit | 13.93 | 14.45 |
| OPM % | 6.75% | 6.08% |
| Other Income | 5.93 | 6.44 |
| Interest | 1.81 | 1.94 |
| Depreciation | 3.09 | 3.04 |
| Profit Before Tax | 18.06 | 18.96 |
| Tax % | 27.35% | 27.16% |
| Net Profit | 13.12 | 13.82 |
| EPS | 1.59 | 1.67 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-54.1%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
22.12%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 16.5968 | 16.6 |
| Reserves | 45.8721 | 58.88 |
| Borrowings | 13.83 | 19.21 |
| Other Liabilities | 43.5 | 58.71 |
| Total Liabilities | 119.7993 | 153.4 |
| Fixed Assets | 21.289 | 20.38 |
| CWIP | 0.3581 | 2.57 |
| Investments | 1.65 | 1.88 |
| Other Assets | 96.5 | 128.57 |
| Total Assets | 119.7993 | 153.4 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 4.8921 |
| Cash from Investing Activity | -3.4599 |
| Cash from Financing Activity | -0.52 |
| Net Cash Flow | 0.9122 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 237.33 |
| ROCE % | 10.38% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 61.38% | 61.38% | 61.38% | 61.38% |
| FIIs % | 0.3% | 0.49% | 0.03% | 0.08% |
| DIIs % | 0.01% | 0% | 0% | 0% |
| Public % | 23.11% | 22.72% | 23.56% | 23.68% |
| No. of Shareholders | 18,503 | 16,562 | 16,189 | 15,863 |
Major Shareholders (>1%)
- Haresh Kapurlal MehtaPromoter and Promoter Group20.22%
- Mehta Rishit HareshbhaiPromoter and Promoter Group12.65%
- Harshit Haresh MehtaPromoter and Promoter Group10.39%
- Rita H MehtaPromoter and Promoter Group8.05%
As of 2026-06-30View all shareholders →